AbbVie Inc.
ABBV
Κατάταξη σε μετοχές
#25
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Τιμή μετοχής
$282.96
Τελευταίος συγχρονισμός: 2026-10-19
Κεφαλαιοποίηση
$500.02B
Αλλαγή (1 ημέρα)
-0.75%
Αλλαγή (1 έτος)
22.62%
Χώρα
US
Εμπόριο AbbVie Inc. (ABBV)
Κατηγορία
Healthcare
Δείκτης P/S για AbbVie Inc. (ABBV)
Δείκτης P/S στις February 2026 TTM: 6.69
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή μετοχής της AbbVie Inc., ο τρέχων δείκτης P/S (TTM) είναι 6.69. Στο τέλος του 2026, ο δείκτης ήταν 0.
Ιστορικό P/S για την AbbVie Inc. από 2026 έως 2026
Δείκτης P/S στο τέλος κάθε έτους
| Έτος | P/S Ratio | Αλλαγή |
|---|---|---|
| Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες. | ||
Δείκτης P/S για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | P/S Ratio | Διαφορά P/S Ratio | Χώρα |
|---|---|---|---|
| 14.32 | 114.06% |
US
|
|
| 6.16 | -7.92% |
US
|
|
| 5.48 | -18.06% |
US
|
|
| 4.66 | -30.37% |
CH
|
|
| 5.52 | -17.48% |
CH
|
